Coherus Oncology, Inc.
CHRS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $158,084 | $313,562 | $614,830 | $1,204,176 |
| - Cash | $125,987 | $102,891 | $63,547 | $417,195 |
| + Debt | $298,647 | $480,842 | $480,422 | $419,023 |
| Enterprise Value | $330,744 | $691,513 | $1,031,705 | $1,206,004 |
| Revenue | $266,960 | $257,244 | $211,042 | $326,551 |
| % Growth | 3.8% | 21.9% | -35.4% | – |
| Gross Profit | $149,407 | $98,252 | $140,959 | $268,960 |
| % Margin | 56% | 38.2% | 66.8% | 82.4% |
| EBITDA | $60,941 | -$193,939 | -$255,581 | -$260,687 |
| % Margin | 22.8% | -75.4% | -121.1% | -79.8% |
| Net Income | $28,507 | -$237,892 | -$291,754 | -$287,100 |
| % Margin | 10.7% | -92.5% | -138.2% | -87.9% |
| EPS Diluted | 0.25 | -2.53 | -3.76 | -3.81 |
| % Growth | 109.9% | 32.7% | 1.3% | – |
| Operating Cash Flow | -$20,440 | -$174,884 | -$241,124 | -$37,432 |
| Capital Expenditures | $0 | -$286 | -$2,039 | -$1,289 |
| Free Cash Flow | -$20,440 | -$175,170 | -$243,163 | -$38,721 |